Acrylamide

CASRN 79-06-1

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (34 pp, 324 K) last updated: 03/22/2010

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
2 x10-3 Nervous Degenerative nerve changes HED (BMDL): 0.053
mg/kg-day
30 Medium/High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (34 pp, 324 K) last updated: 03/22/2010

RfC (mg/m3) System Basis PoD Composite UF Confidence
6 x10-3 Nervous Degenerative nerve changes HEC5 (BMDL): 0.18
mg/m3
30 Medium

Cancer Assessment


Weight of Evidence for Cancer (PDF) (34 pp, 324 K) last updated: 03/22/2010

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • In accordance with the Guidelines for Carcinogen Risk Assessment U.S. EPA, 2005, acrylamide (AA) is characterized as "likely to be carcinogenic to humans."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (34 pp, 324 K)

Oral Slope Factor: 5 x10 -1 per mg/kg-day
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
Tumor site(s): Reproductive, Endocrine
Tumor type(s): thyroid tumors and tunica vaginalis mesotheliomas (Johnson et al., 1986)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (34 pp, 324 K)

Inhalation Unit Risk: 1 x10 -4 per µg/m3
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
Tumor site(s): Reproductive, Endocrine
Tumor type(s): thyroid tumors and tunica vaginalis mesotheliomas (Johnson et al., 1986)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.